|
US7037916B2
(en)
*
|
1999-07-15 |
2006-05-02 |
Pharmacopeia Drug Discovery, Inc. |
Pyrimidine derivatives as IL-8 receptor antagonists
|
|
GB0016877D0
(en)
*
|
2000-07-11 |
2000-08-30 |
Astrazeneca Ab |
Chemical compounds
|
|
US6867300B2
(en)
*
|
2000-11-17 |
2005-03-15 |
Bristol-Myers Squibb Company |
Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors
|
|
US6670357B2
(en)
*
|
2000-11-17 |
2003-12-30 |
Bristol-Myers Squibb Company |
Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors
|
|
JP4510442B2
(ja)
*
|
2001-06-26 |
2010-07-21 |
ブリストル−マイヤーズ スクイブ カンパニー |
ＴＮＦ−α発現のＮ−ヘテロ環インヒビター
|
|
NZ531854A
(en)
*
|
2001-11-01 |
2006-03-31 |
Janssen Pharmaceutica Nv |
Aminobenzamide derivatives as glycogen synthase kinase 3beta inhibitors
|
|
TWI329105B
(en)
|
2002-02-01 |
2010-08-21 |
Rigel Pharmaceuticals Inc |
2,4-pyrimidinediamine compounds and their uses
|
|
DE60325469D1
(de)
|
2002-04-23 |
2009-02-05 |
Bristol Myers Squibb Co |
Als kinase inhibitoren geeignete arylketonpyrrolotriazin-verbindungen
|
|
BR0309669A
(pt)
*
|
2002-04-23 |
2005-03-01 |
Bristol Myers Squibb Co |
Compostos de anilina de pirrolo-triazina úteis como inibidores de cinase
|
|
IL166241A0
(en)
|
2002-07-29 |
2006-01-15 |
Rigel Pharmaceuticals Inc |
Method of treating or preventing autoimmune diseases with 2,4-pyrimidinedinediamine compounds
|
|
CN1717396A
(zh)
*
|
2002-11-28 |
2006-01-04 |
舍林股份公司 |
Chk－、Pdk－和Akt－抑制嘧啶,其制备及作为药物的用途
|
|
US6909001B2
(en)
|
2002-12-12 |
2005-06-21 |
Pharmacia Corporation |
Method of making tricyclic aminocyanopyridine compounds
|
|
CA2508780A1
(en)
*
|
2002-12-12 |
2004-07-01 |
Pharmacia Corporation |
Method of using aminocyanopyridine compounds as mitogen activated protein kinase-activated protein kinase-2 inhibitors
|
|
WO2004069829A1
(en)
*
|
2003-01-10 |
2004-08-19 |
Pharmacopeia Drug Discovery, Inc. |
(2s)-2-((pyrimidin-4-yl)amino)-4-methylpentanoic acid aminoethylamid derivatives as il-8 receptor modulators for the treatment of atherosclerosis and rheumatoid arthritis
|
|
EP1927594A1
(en)
*
|
2003-01-14 |
2008-06-04 |
Arena Pharmaceuticals, Inc. |
1,2,3-Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
|
|
BRPI0406761A
(pt)
*
|
2003-01-14 |
2005-12-20 |
Arena Pharm Inc |
Derivados de arila e heteroarila 1,2,3-trissubstituìdos como moduladores do metabolismo e a profilaxia e tratamento de distúrbios relacionados a estes tais como diabetes e hiper-glicemia
|
|
UA92450C2
(ru)
*
|
2003-01-14 |
2010-11-10 |
Арена Фармасьютикалз, Инк. |
1,2,3-тризамещенные арильные и гетероарильные производные как модуляторы метаболизма, профилактика и лечение расстройств, связанных с ним, таких как диабет и гипергликемия
|
|
KR20050099525A
(ko)
|
2003-02-05 |
2005-10-13 |
브리스톨-마이어스 스큅 컴퍼니 |
피롤로트리아진 키나제 억제제의 제조 방법
|
|
US20050014753A1
(en)
*
|
2003-04-04 |
2005-01-20 |
Irm Llc |
Novel compounds and compositions as protein kinase inhibitors
|
|
ATE522525T1
(de)
*
|
2003-05-01 |
2011-09-15 |
Bristol Myers Squibb Co |
Arylsubstituierte pyrazolamidverbindungen, die als kinase-inhibitoren von nutzen sind
|
|
WO2005000298A2
(en)
*
|
2003-06-03 |
2005-01-06 |
Novartis Ag |
5-membered heterocycle-based p-38 inhibitors
|
|
US7465738B2
(en)
|
2003-06-16 |
2008-12-16 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as promoters of SMN2
|
|
US7504396B2
(en)
*
|
2003-06-24 |
2009-03-17 |
Amgen Inc. |
Substituted heterocyclic compounds and methods of use
|
|
AR045047A1
(es)
*
|
2003-07-11 |
2005-10-12 |
Arena Pharm Inc |
Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
|
|
US8178671B2
(en)
|
2003-07-30 |
2012-05-15 |
Rigel Pharmaceuticals, Inc. |
Methods of treating or preventing autoimmune diseases with 2, 4-pyrimidinediamine compounds
|
|
PT2287156E
(pt)
*
|
2003-08-15 |
2013-08-26 |
Novartis Ag |
2,4-di(fenilamino)-pirimidinas úteis no tratamento de doenças neoplásicas, desordens inflamatórias e do sistema imunitário
|
|
PE20050483A1
(es)
|
2003-10-31 |
2005-08-25 |
Arena Pharm Inc |
Derivados de tetrazol de formula (i), sus composiciones farmaceuticas y procesos para producir composiciones farmaceuticas
|
|
EP1687274A1
(en)
*
|
2003-11-20 |
2006-08-09 |
Warner-Lambert Company LLC |
Androgen receptor modulators
|
|
US7459562B2
(en)
*
|
2004-04-23 |
2008-12-02 |
Bristol-Myers Squibb Company |
Monocyclic heterocycles as kinase inhibitors
|
|
JP4812763B2
(ja)
|
2004-05-18 |
2011-11-09 |
ライジェル ファーマシューティカルズ， インコーポレイテッド |
シクロアルキル置換ピリミジンジアミン化合物およびそれらの用途
|
|
EP1598343A1
(de)
*
|
2004-05-19 |
2005-11-23 |
Boehringer Ingelheim International GmbH |
2-Arylaminopyrimidine als PLK Inhibitoren
|
|
MXPA06014129A
(es)
*
|
2004-06-04 |
2007-03-07 |
Arena Pharm Inc |
Derivados de arilo y heteroarilo sustituidos como moduladores del metabolismo y profilaxis y tratamiento de trastornos relacionados con los mismos.
|
|
US7253167B2
(en)
*
|
2004-06-30 |
2007-08-07 |
Bristol-Myers Squibb Company |
Tricyclic-heteroaryl compounds useful as kinase inhibitors
|
|
TW200600513A
(en)
*
|
2004-06-30 |
2006-01-01 |
Bristol Myers Squibb Co |
A method for preparing pyrrolotriazine compounds
|
|
US7504521B2
(en)
*
|
2004-08-05 |
2009-03-17 |
Bristol-Myers Squibb Co. |
Methods for the preparation of pyrrolotriazine compounds
|
|
TW200618803A
(en)
|
2004-08-12 |
2006-06-16 |
Bristol Myers Squibb Co |
Process for preparing pyrrolotriazine aniline compounds useful as kinase inhibitors
|
|
CA2581454A1
(en)
*
|
2004-09-23 |
2006-03-30 |
Reddy Us Therapeutics, Inc. |
Novel pyrimidine compounds, process for their preparation and compositions containing them
|
|
AU2005289426A1
(en)
*
|
2004-09-27 |
2006-04-06 |
Amgen Inc. |
Substituted heterocyclic compounds and methods of use
|
|
GB2420559B
(en)
|
2004-11-15 |
2008-08-06 |
Rigel Pharmaceuticals Inc |
Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses
|
|
EP1814878B1
(en)
|
2004-11-24 |
2012-01-04 |
Rigel Pharmaceuticals, Inc. |
Spiro-2, 4-pyrimidinediamine compounds and their uses
|
|
MY148521A
(en)
*
|
2005-01-10 |
2013-04-30 |
Arena Pharm Inc |
Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
|
|
EP1856135B1
(en)
|
2005-01-19 |
2009-12-09 |
Rigel Pharmaceuticals, Inc. |
Prodrugs of 2,4-pyrimidinediamine compounds and their uses
|
|
US20060247263A1
(en)
*
|
2005-04-19 |
2006-11-02 |
Amgen Inc. |
Substituted heterocyclic compounds and methods of use
|
|
US8153791B2
(en)
*
|
2005-12-21 |
2012-04-10 |
Janssen Pharmaceutica N.V. |
Substituted pyrimidinyl oxime kinase inhibitors
|
|
US8278446B2
(en)
*
|
2005-12-21 |
2012-10-02 |
Janssen Pharmaceutica N.V. |
Process for preparing substituted diaminopyrimidine oximes
|
|
WO2007081630A2
(en)
*
|
2005-12-21 |
2007-07-19 |
Janssen Pharmaceutica, N.V. |
Substituted pyrimidinyl kinase inhibitors
|
|
WO2007109783A2
(en)
*
|
2006-03-23 |
2007-09-27 |
Janssen Pharmaceutica, N.V. |
Substituted pyrimidine kinase inhibitors
|
|
JP2009545592A
(ja)
|
2006-07-31 |
2009-12-24 |
プリーシス・ファーマシューティカルズ・インコーポレイテッド |
コード化小分子ライブラリーからのオーロラキナーゼ阻害剤
|
|
US8119798B2
(en)
|
2006-08-01 |
2012-02-21 |
Glaxosmithkline Llc |
P38 kinase inhibitors
|
|
ES2633318T3
(es)
|
2006-10-23 |
2017-09-20 |
Cephalon, Inc. |
Derivados bicíclicos fusionados de 2,4-diaminopirimidina como inhibidores de ALK y c-Met
|
|
US20100137398A1
(en)
*
|
2007-05-04 |
2010-06-03 |
Novartis Ag |
Use of hdac inhibitors for the treatment of gastrointestinal cancers
|
|
BRPI0814432A2
(pt)
*
|
2007-07-17 |
2017-05-09 |
Rigel Pharmaceuticals Inc |
pirimidinadiaminas substituídas por amina cíclica como inibidores de pkc
|
|
PT2203173E
(pt)
|
2007-10-26 |
2016-03-15 |
Academisch Ziekenhuis Leiden |
Resumo
|
|
AU2009215430B2
(en)
*
|
2008-02-22 |
2015-02-12 |
Rigel Pharmaceuticals, Inc. |
Use of 2,4-pyrimidinediamines for the treatment of atherosclerosis
|
|
EP2119783A1
(en)
|
2008-05-14 |
2009-11-18 |
Prosensa Technologies B.V. |
Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means
|
|
US20110245156A1
(en)
*
|
2008-12-09 |
2011-10-06 |
Cytokine Pharmasciences, Inc. |
Novel antiviral compounds, compositions, and methods of use
|
|
AT509266B1
(de)
*
|
2009-12-28 |
2014-07-15 |
Univ Wien Tech |
Substituierte pyridine und pyrimidine
|
|
MX2012008141A
(es)
*
|
2010-01-13 |
2012-08-03 |
Glaxosmithkline Llc |
Compuestos y metodos.
|
|
MX2012014158A
(es)
|
2010-06-04 |
2013-02-07 |
Hoffmann La Roche |
Derivados de aminopirimidina como moduladores de proteina cinasa rica repeticiones leucina 2 (lrrk2).
|
|
SG188548A1
(en)
|
2010-09-22 |
2013-04-30 |
Arena Pharm Inc |
Modulators of the gpr119 receptor and the treatment of disorders related thereto
|
|
PH12013500880A1
(en)
|
2010-11-10 |
2013-07-01 |
Hoffmann La Roche |
Pyrazole aminopyrimidine derivatives as lrrk2 modulators
|
|
CA2862628C
(en)
|
2012-01-27 |
2021-08-24 |
Prosensa Technologies B.V. |
Rna modulating oligonucleotides with improved characteristics for the treatment of duchenne and becker muscular dystrophy
|
|
CN102952084A
(zh)
*
|
2012-11-15 |
2013-03-06 |
大连九信生物化工科技有限公司 |
一种4，6－二氯－2－甲硫基－5－硝基嘧啶的合成方法
|
|
AU2014369031A1
(en)
|
2013-12-20 |
2016-07-07 |
Signal Pharmaceuticals, Llc |
Substituted Diaminopyrimidyl Compounds, compositions thereof, and methods of treatment therewith
|
|
AU2016205361C1
(en)
|
2015-01-06 |
2021-04-08 |
Arena Pharmaceuticals, Inc. |
Methods of treating conditions related to the S1P1 receptor
|
|
CA3002551A1
(en)
|
2015-06-22 |
2016-12-29 |
Arena Pharmaceuticals, Inc. |
Crystalline l-arginine salt of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid(com pound 1)for use in s1p1 receptor-associated disorders
|
|
WO2017151409A1
(en)
|
2016-02-29 |
2017-09-08 |
University Of Florida Research Foundation, Incorporated |
Chemotherapeutic methods
|
|
LT3442947T
(lt)
*
|
2016-04-15 |
2023-09-11 |
Epizyme, Inc. |
Aminu pakeisti arilo arba heteroarilo junginiai, kaip ehmt1 ir ehmt2 inhibitoriai
|
|
CA3053418A1
(en)
|
2017-02-16 |
2018-08-23 |
Arena Pharmaceuticals, Inc. |
Compounds and methods for treatment of primary biliary cholangitis
|
|
JP6722365B1
(ja)
*
|
2017-07-18 |
2020-07-15 |
ロンザ リミテッドＬｏｎｚａ Ｌｉｍｉｔｅｄ |
塩素化ｓ−プロピル−チオバルビツル酸の製造方法
|
|
US10342786B2
(en)
|
2017-10-05 |
2019-07-09 |
Fulcrum Therapeutics, Inc. |
P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
|
|
CA3127373A1
(en)
|
2017-10-05 |
2019-04-11 |
Fulcrum Therapeutics, Inc. |
P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd
|
|
CA3102136A1
(en)
|
2018-06-06 |
2019-12-12 |
Arena Pharmaceuticals, Inc. |
Methods of treating conditions related to the s1p1 receptor
|
|
PT3966206T
(pt)
|
2019-05-10 |
2023-11-10 |
Deciphera Pharmaceuticals Llc |
Inibidores de autofagia de heteroarilaminopirimidina amida e métodos de utilização dos mesmos
|
|
US11530206B2
(en)
|
2019-05-10 |
2022-12-20 |
Deciphera Pharmaceuticals, Llc |
Phenylaminopyrimidine amide autophagy inhibitors and methods of use thereof
|
|
JP7626722B2
(ja)
|
2019-06-17 |
2025-02-04 |
デシフェラ・ファーマシューティカルズ，エルエルシー |
アミノピリミジンアミドオートファジー阻害剤およびその使用方法
|